ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)

Cortes Salgado, A.Perez Garcia, J. M.Cortez Castedo, S. P.Gion Cortes, M.Morales Murillo, S.Blancas Lopez-Barajas, I.Blanch, S.Calvo Plaza, I.Diaz Fernandez, N.Marme, F.Martinez Bueno, A.Taberner Bonastre, M. T.De laurentiis, M.Ruiz Borrego, M.Schmid, P.Guarneri, V.Gligorov, J.Sampayo-Cordero, M.Llombart Cussac, A.Cortes, J.2023-05-032023-05-032022-05-050923-7534http://hdl.handle.net/10668/21907enATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)conference outputopen access10.1016/j.annonc.2022.03.2241569-8041http://www.annalsofoncology.org/article/S0923753422006032/pdf792494100208